The Polynesian languages are the second newest in the world (Creole being the newest). They only emerged in the last millennium. The peoples who left Taiwan (see The Origin of South Pacific Languages) around 3000 BC had established clear settlements in Samoa and Tonga by 1200 BC. They reached Tahiti by 200 AD, when prevailing westerlies kept them from exploring more islands east of Tahiti. Between 1140 and 1260 AD the direction of the prevailing winds shifted and they reached New Caledonia and New Zealand.
The word for bird is the same in Tongan, Samoan, Tahitian, Maori and Hawaiian.
The Austronesian language family is divided into three subfamilies:
Western – Tagalog, Indonesian and Javanese
Central – Tetum (spoken in Timur and Kamura) and Keo (spoken in western Indonesia)
Eastern – Oceanic (aka South Pacific, aka Polynesian) languages
The Polynesian languages, the most recent to develop, tend to have the smallest number of sounds with short syllables and no consonant clusters or long words. As language groups split off the number of words tends to decrease in proportion to the decrease in speaker numbers.
Most linguists believe the first languages originating in Africa were click languages. They had the largest number of sounds, and as languages evolved there was steady loss of sonic material. This most obvious in recently evolved languages. For example most Polynesian languages use the same pronoun for he and she.
For over two decades, Dr. Andrew Wakefield has been vilified for reporting what countless parents saw with their own eyes — that their healthy children regressed into autism following vaccination.
Now, in our landmark McCullough Foundation report, Determinants of Autism Spectrum Disorder, we bring together over 300 studies confirming that vaccines are the dominant risk factor among all environmental and iatrogenic influences.
BREAKING — Landmark Report Finds Vaccination Is the Dominant Risk Factor for Autism Spectrum Disorder
In this exclusive interview, Dr. Wakefield reflects on how he first identified gastrointestinal disease in autistic children, the decades of censorship that followed, and why the truth can no longer be suppressed.
“The parents were right — the doctors were wrong,” Wakefield said. “We scoped the children, we saw the inflammation, and it was something brand new. Had we been allowed to continue, we would have known the full mechanism years ago.”
Academia’s Campaign of Indoctrination Against Wakefield
Students were instructed to dismiss his work as “discredited” without ever reading the Lancet paper or the clinical evidence it described.
This was not education — it was indoctrination, a form of scientific brainwashing designed to preserve the narrative that “vaccines cannot cause autism,” regardless of mounting evidence to the contrary.
It exposed how deeply the Bio-Pharmaceutical Complex has infiltrated academia — shaping generations of public-health professionals who are rewarded not for independent thought, but for obedience.
They Told Me I’d Never Have a Career. I Told the Truth Anyway.
The Lancet Debacle & the Vaccine Cartel’s Retaliation
As detailed in our report, the controversy began in 1998, when Dr. Wakefield and twelve colleagues published their Lancet case series describing intestinal inflammation and regression following the MMR vaccine. They did not claim proof of causation — only that the evidence warranted further investigation. Yet, after the National Childhood Vaccine Injury Act shielded manufacturers from liability and the Omnibus Autism Proceeding began exposing vaccine-injury claims, powerful interests moved to silence dissent.
In 2004, journalist Brian Deer — working for a Rupert Murdoch–owned paper — launched a coordinated smear campaign accusing Wakefield of fraud, just as thousands of families were petitioning the U.S. vaccine court. Under immense pressure from the pharmaceutical establishment, The Lancet capitulated in 2011, retracting the paper despite no errors in data or methodology.
This moment marked the triumph of censorship over scientific inquiry.
Decades of Progress, Lost to Censorship
Had Wakefield and others been allowed to continue their research, we might have understood and successfully treated autism decades ago.
Promising leads on gut–brain dysfunction, immune dysregulation, and mitochondrial injury were buried under propaganda and professional reprisals. Entire generations of children have since been lost to diagnostic labeling rather than biomedical intervention — while universities, journals, and health agencies doubled down on denial.
The human cost of that censorship is incalculable: millions of families left without answers, and an entire field of autism research set back a quarter-century.
Today, the McCullough Foundation’s comprehensive analysis revives that lost line of inquiry — uniting the epidemiologic, mechanistic, and clinical evidence that vindicates what Wakefield first observed in the 1990s.
Alzheimer’s disease is commonly thought to result from abnormal plaque buildup in the brain that gradually destroys brain tissue. Almost all Alzheimer’s research for decades has been directed toward eliminating amyloid, even after the basis for much of this work was shown to stem from fraudulent research
The billions spent on amyloid Alzheimer’s research have only produced three drugs, all of which offer minuscule benefits and severe side effects
In contrast, affordable and straightforward treatments that reduce dementia or the preceding cognitive impairment have been maligned and buried by the medical industry
DMSO for example, has incredible neuroprotective qualities that have spared many stroke and spinal cord injury victims from a life of “incurable” disability. Decades of forgotten research also show it treats cognitive impairment and dementia
This article will review the great amyloid scam and the simple therapies for cognitive decline we’re never told about
Medicine is strongly biased towards adopting biochemical models of disease as this facilitates costly therapeutics being developed for each disease and hence sustains the medical industry. Unfortunately, in many cases, the biochemical approach to disease, at best, can manage symptoms, and as a result, many conditions remain “incurable” while non-patentable natural therapies that can cure them languish in obscurity.
That’s why, despite spending an ever increasing amount of money on Alzheimer’s research (e.g., the NIH spent 2.9 billion in 2020 and 3.9 billion in 20241), we’ve still failed to make any real progress on the disease. This is particularly remarkable given the vast costs to the country (e.g., last year Alzheimer’s was estimated to cost the United States 360 billion dollars2) and the even greater social costs that accompany it.
The Amyloid Juggernaut
In 1906, plaques (of amyloid) in the brain were identified as the cause of Alzheimer’s disease. As the years have gone by, the majority of research for treating Alzheimer’s disease has been targeted at eliminating these plaques.
[…]
The consistent failure of the amyloid model to cure Alzheimer’s gradually invited increasing skepticism towards it, which resulted in more and more scientists studying alternative models of the disease. Before long, they found other factors played a far more significant role in causing the disease (e.g., chronic inflammation), and by 2006, this perspective appeared poised to change the direction of Alzheimer’s research.
In response, the amyloid proponents pivoted to defending their failed hypothesis was due not to amyloid clumps, but rather toxic parts of it (oligomers) and a Nature 2006 paper appeared which identified a previously unknown toxic oligomer, Aβ*56, and provided proof that it caused dementia in rats.5
This paper cemented both the amyloid beta and toxic oligomer hypotheses (as it provided the proof many adherents to the theory had been waiting for) and rapidly became one of the most cited works in the field of Alzheimer’s research. Its authors rose to academic stardom, produced further papers validating their initial hypothesis, and billions more were invested by both the NIH and the pharmaceutical industry in research of the amyloid and toxic oligomer hypothesis.
[…]
The Amyloid Scandal
At the end of 2021, a neuroscientist physician was hired by investors to evaluate an experimental Alzheimer’s drug and discovered signs that its data consisted of doctored Western Blots (and therefore erroneous assessments of what oligomers were present within research subjects’ brains).7 As he explored the topic further, he discovered other papers within the Alzheimer’s literature had been flagged for containing doctored Western Blots.
[…]
Before long, the neuroscientist noticed three of those suspect papers had been published by the same author and decided to investigate the author’s other publications. This led him to the seminal 2006 Alzheimer’s publication, which contained clear signs of fraud.9
As investigation then uncovered 20 doctored papers written by the author, 10 of which pertained to Aβ*56 (along with a co-researcher attesting to earlier scientific misconduct by the author).
The Amyloid Industry
One of the remarkable things about this monumental fraud was how little was done about it. For example, the NIH was notified in January 2022, yet in May 2022, beyond nothing being done, the NIH gave the suspect researcher a coveted $764,792 research grant (signed off by another one of the authors of the 2006 paper10).
In July 2022, Science published an article exposing the incident and the clear fraud that had occurred.11 Despite this, the researcher was allowed to remain in his position as a tenured medical school professor.12 It was not until June 2024 that the 2006 article was retracted at the request of the authors13 — all of whom denied being at fault and insisted the doctored images had not affected the article’s conclusions.
Eventually, on January 29, 2025, during his confirmation hearing, RFK cited the paper as an example of the institutional fraud and wasted tax dollars within the NIH, and a few days later, the suspect researcher announced his resignation from the medical school professorship (while still maintaining his innocence).14
This odd behavior (e.g., the medical field continues to insist the proven fraud has not disproven the Amyloid hypothesis) likely results from how much money is at stake — beyond the research dollars, roughly 7 million adults have Alzheimer’s — equating to hundreds of billions in potential (Medicare funded) sales each year.15
The Failed Amyloid Drugs
Recently, a monoclonal antibody that made immune cells target amyloid demonstrated limited success in treating Alzheimer’s — which was embraced as revolutionary by the medical community, the pharmaceutical industry, and drug regulators. In turn, the first new drug received accelerated approval (which the FDA proudly announced).16 The second then received a quiet backdoor approval (due to the immense controversy surrounding the first),17 and the third was partially approved a year and a half later.18
Each year, JP Morgan (Chase Bank) hosts a private conference for pharmaceutical investors that sets the tone for the entire industry. In 2023, its focus (covered in detail here) was on the incredible profitability of the new Alzheimer’s drugs and the GLP-1s like Ozempic (which the FDA has also relentlessly promoted). Most remarkably, the (widely viewed as corrupt) FDA commissioner was a keynote speaker, and a few days before the conference, had enacted the second backdoor approval.
However, despite the rosy pictures painted around the drugs (which each attacked different aspects of amyloids), they were highly controversial as:
• The FDA’s independent advisory panel, in a very unusual move, voted 10-0 (with one abstaining) against approving Aduhelm, the first amyloid drug (which targeted amyloid plaques), but the FDA approved it anyways. In a highly unprecedented move, three of the advisors then resigned, calling it “probably the worst drug approval decision in recent U.S. history.”19
• That drug was priced at $56,000 a year — making it sufficient to bankrupt Medicare, (which attracted a Congressional investigation).20
• Brain swelling or brain bleeding was found in 41% of patients enrolled in its studies.21 Additionally, headaches (including migraines and occipital neuralgia), falls, diarrhea, confusion, and delirium were also notably elevated compared to placebo.
• No improvement in Alzheimer’s was noted; rather one analysis found it slowed the progression of Alzheimer’s by 20% (although this could have been a protocol artifact rather than a real effect).
The second monoclonal antibody (which targeted amyloid precursors) had a somewhat better risk benefit profile22 (only 21% experienced brain bleeding and swelling due to reduced targeting of stable amyloid plaques), and 26.4% reduction in the progression of Alzheimer’s was detected in the trial (which for context, translated to a 0.45 reduction on a scale where a reduction of at least 1 to 2 points is needed to create an impact which is in any way meaningful for a patient).
The third monoclonal (which targeted amyloid plaques thought to be more pathologic)23 was also contested as it caused 36.8% of recipients to develop brain bleeding or swelling, like the other amyloid medications, frequently caused headaches and infusion reactions (e.g., nausea, vomiting, changes in blood pressure, hypersensitive reactions or anaphylaxis) and there were reasons to suspect the trial had greatly overstated its minimal benefits.
Remarkably, despite widespread protest against the third drug, the FDA’s new advisory panel voted unanimously in favor of it, even though it had a very similar mechanism, efficacy, and toxicity to the previously unanimously rejected amyloid drug.
It should therefore come as no surprise that, when the British Medical Journal conducted an independent investigation, it found that, within publicly available databases, 9 out of 9 (assessable) members of the advisory committee had significant financial conflicts of interest.24
Fortunately, despite the aggressive promotion of amyloid drugs and the industry’s best attempts to promote the sector, the market somewhat recognized how bad they were. The first drug had its price halved (then was withdrawn as no one wanted it — making around 5 million dollars total),25 while the other two have had very modest sales (e.g., 290 million for the most popular one26).
What Amyloids Drugs Show Us
From this, four things stand out:
• These drugs consistently damage brain tissue, indicating that their mechanism of action was inherently dangerous (e.g., it creates brain swelling by causing immune cells attacking amyloid also to attack brain tissue, or it creates brain bleeding by removing amyloid plaque that patches vessel walls and stabilizes brain tissue). Remarkably, despite this issue being recognized, it has not deterred the usage of these class drugs.
• An absolutely absurd amount of money and time has been wasted on this endeavor due to the medical field’s need to find a patentable drug.
• The focus on these lucrative drugs has diverted attention from other (off-patent) treatments that are more likely to help Alzheimer’s patients.
For example, a randomized controlled trial which gave MCTs derived from coconut found that over 6 months,27 80% remained stable or improved — which for context, is better than what any of the amyloid drug trials showed, and more importantly, does not cause brain bleeds (and costs a lot less than the annual rough $30,000 cost for those drugs).
[…]
Likewise, very few are aware of a 2022 study that should have revolutionized the entire Alzheimer’s field:28
[…]
DMSO and Dementia
Dimethyl Sulfoxide (DMSO) is a naturally occurring compound that has a variety of unique healing properties that allow it to rescue tissues from dying and revive those damaged from previous injuries — best demonstrated by decades of evidence showing DMSO can heal strokes, brain bleeds, severe concussions, and spinal cord injuries and save patients from a lifetime of paralysis.
[…]
Numerous studies support these experiences:
• When rats had their carotid arteries surgically modified to reduce the blood going to the brain, DMSO prevented both the neuronal damage and the significant loss of spatial memory and learning that otherwise occurred.32
• In a similar study, rats who developed persistent and severe memory impairment from reduced brain blood flow received DMSO and FDP for 7 days, which improved their memory by 54%, nearly reaching the cognitive function rats whose blood flow was never cut off.33,34
• In rats, daily DMSO counteracted memory impairment induced by intracerebroventricular STZ infusions,35 while in a similar study,36 DMSO and Ginkgo biloba improved learning and memory in rats given Alzheimer’s disease.
[…]
These results have also been replicated in humans:
• In 18 patients with probable Alzheimer’s after three months, DMSO greatly improved memory, concentration, and communication, alongside a significant decrease in disorientation in time and space.39
• In 104 elderly adults with dementia due to cerebrovascular diseases, concussions, or Parkinson’s, DMSO combined with amino acids significantly improved their cognition and motor function.40
• In 100 patients with cerebrovascular diseases (many of whom had dementia),41 DMSO caused almost all to have their cardiovascular parameters improve and:
“Recovery from the general symptoms was positive; there were favorable changes which were reflected in a feeling of well being, the recovery of agility, changes of mood from depressed to gay, improvement of sleeping, and clearer speech. As regards the ‘focal’ results, accelerated recovery from hemiplegia and hemiparesia was registered. A speedier recovery of speech in cases of defined or indicated aphasia took place.”
… “The fact of the matter is that the posturing with China is really all about obscuring the US’s economic demise, while also gaining leverage, sabotaging, and undercutting China as much as possible.
This is because the US political class has no answers at all for its own failing economy, and thus must rely exclusively on the strategy of hamstringing its competitors. It’s all an act meant to forestall China’s takeover to buy time for the US corporo-political class to figure out a way to reset US’s runaway debt spiral and hyper-financialized Babylonian tower—which many now believe will happen by crypto-izing US debt:
AMERICA WANTS TO HAVE ALL THEIR 37 TRILLION DEBT IN CRYPTO then crash the market, eliminating the debt.
Translation: EXPORT THE DEBT TO OTHER NATIONS
This plan was enumerated in particular at the Eastern Economic Forum by Putin’s special advisor Anton Kobyakov:
U.S. CRYPTO PLOT EXPOSED: Wiping $35 trillion debt on world’s dime
“The US will solve their financial problems at the expense of the whole world, driving everyone into the crypto-currency cloud. Over time, when part of the US state debt will be placed in stablecoins, the US will devalue this debt,” Putin’s advisor Kobyakov revealed.
Putin’s advisor Kobyakov: The U.S. has devised a crypto scheme to erase its massive debt at the world’s expense.
The U.S. is now trying to rewrite the rules of the gold and cryptocurrency markets. Remember the size of their debt—35 trillion dollars. These two sectors (crypto and gold) are essentially alternatives to the traditional global currency system.
Washington’s actions in this area clearly highlight one of its main goals: to urgently address the declining trust in the dollar.
As in the 1930s and the 1970s, the U.S. plans to solve its financial problems at the world’s expense—this time by pushing everyone into the “crypto cloud.” Over time, once part of the U.S. national debt is placed into stablecoins, Washington will devalue that debt.
Put simply: they have a $35 trillion currency debt, they’ll move it into the crypto cloud, devalue it—and start from scratch.
That’s the reality for those who are so enthusiastic about crypto.
When a guy managing $13T says owning crypto makes sense because governments will keep killing their currencies… that’s your clue. The system’s insiders are quietly admitting what Bitcoiners knew all along. Watch what they do, not what they preach.
“As stated earlier, at this point the theatrics with China and various tariff seesaws appear more a distraction and desperate time-buying theater.
The US is insolvent and its entire economy is increasingly hinged on nothing more than an empty AI capital washing machine spinning the same inflating ball of lint in circles as the plebs are immiserated beyond the breaking point……..”
Ultra-Orthodox men attend a rally in Occupied al-Quds against plans to force them to serve in the Israeli military, October 30, 2025. (Photo by AP)
Press TV
Tens of thousands of ultra-Orthodox Jewish settlers have staged a massive protest in Occupied al-Quds against plans to draft them into the Israeli military, declaring they “would rather go to jail.”
Worried about the Israeli regime’s military corrupting their religious traditions, the Haredim, which make up about 14% of the Israeli settlers’ population, took to the streets on Thursday, leading to the regime’s deployment of more than 2,000 troops to confront them.
The protest largely crippled the occupied city, with roads closed and public transportation halted by the massive crowds.
One teenager reportedly died at the protest after falling from a building under construction next to the protest. After several hours, police used water cannons to disperse the protesters who refused to leave the streets.
The demonstrators oppose military service because they believe full-time study in religious seminaries is their highest duty.
Their political representatives pursue a permanent draft exemption as well as increased community budgets. Nevertheless, they have failed to secure the budget that allows full-time religious study with stipends, though temporary funding measures remain.
The mass demonstration exposed sharp rifts within settler society and across its political spectrum regarding the long-standing draft exemption granted to ultra-Orthodox Jews, a policy dating back to the regime’s fabrication in 1948.
In August, ultra-Orthodox Jewish leaders and media declared a “War for God” against the Israeli military’s enforcement of draft orders for Haredi men, highlighting the deepening divisions within settler society amid the ongoing war on Gaza.
It took place amid intense pressure on Israeli prime minister Benjamin Netanyahu, whose fragile regime is supported by ultra-Orthodox parties.
The parties withdrew from Netanyahu’s coalition over the summer over his failure to strike a balance between the ultra-Orthodox settlers and the secular Jewish faction demanding that the ultra-Orthodox be drafted into the Israeli military.
Nevertheless, they continue to occasionally align with Netanyahu, driven by their political vulnerability and the need to preserve their coalition’s stability.
The issue has become a major point of contention, especially since the Israeli regime began its genocidal war on Gaza.
The war has reportedly resulted in the deaths of around 900 Israeli soldiers and forced troops to deploy for extended periods during repeated military raids, driven by the intensity of the regime’s assaults on Palestinians.
The Israeli military is now facing an urgent shortage of personnel, with its soldiers fatigued and depleted.
The protest was triggered by the decision to bring the draft legislation for discussion in a Knesset committee next week. This is the first step before the bill can be brought to the general Knesset for a vote.
The exemption was initially granted to small numbers of gifted scholars but has expanded over decades under pressure from powerful political lobbies.
In 2017, the regime declared the exemptions illegal, but has so far failed to include the ultra-Orthodox population in the conscription list.
Elections are currently scheduled for next November, but Netanyahu could likely be forced to call early elections in the next few months.
The global automotive industry is getting ready for potential production cuts and factory shutdowns as it grapples with an ongoing shortage of critical semiconductor chips. At least one has already started pulling back.
Honda Motor Co., Ltd. was the first company to begin reducing or suspending production across its plants in North America. That will continue into next week, according to a company spokesperson.
Production at a Canadian plant that assembles Civic sedans and CR-V SUVs has been slowed, according to a union that represents workers at a supplier to the plant. And the Yomiuri Shimbun, a Japanese newspaper, reports that Honda’s plant in Mexico, which manufactures the HR-V SUV, has been temporarily closed.
The chip crisis plaguing the automotive industry began in September, when the Netherlands took control of Nexperia, a key automotive microchip maker owned by China’s Wingtech Technology. In response, the Chinese Ministry of Commerce blocked exports of some Nexperia products. About 80% of Nexperia’s total end-product capacity is in mainland China.
Nexperia accounts for about 5% of the global automotive silicon discrete market, according to S&P Global Mobility. It mainly sells standard parts that aren’t technologically advanced but are widely used, with hundreds of chips often needed per vehicle.
“I think it’s more than 2,000 small different chips,” said Arno Antlitz, Volkswagen AG’s chief financial officer and chief operating officer, on a call with investors Thursday, according to a FactSet transcript. “And so it makes it also difficult to find alternative solutions because we are not talking about three or five or seven different units, more like thousands.”
The European Automobile Manufacturers’ Association, which represents companies such as Volkswagen and Mercedes-Benz Group, said assembly-line shortages “might only be days away” as existing supplies dry up.
Volkswagen has enough supply to last at least through next week, according to Antlitz. While Mercedes is “covered” in the short term, it’s also “scurrying” around looking for new suppliers, according to its chief executive. A spokesperson for BMW Group said production has been unchanged at its facilities.
“Every day we are pushing actions and projects” back to avoid disruption to production, Stellantis NV Chief Executive Antonio Filosa said on Thursday, adding that the Jeep maker has set up a “war room” to address potential shortages.
Jim Farley, whose Ford Motor Co. has increased purchases from other suppliers in recent weeks, has said that a “very quick breakthrough” is necessary to avoid losses for the entire industry. General Motors Co. has said it is also working to avoid disruptions.
Nissan Motor Co., Ltd on Thursday said it expects a $1.78 billion operating loss in its current fiscal year, partially due to supply chain-related risks. Still, the automaker has said it has enough chips to last until next week without adjusting production.
Meanwhile, the CEO of fellow Japanese automaker Toyota Motor Corp. isn’t very concerned. “I do think there’s some risk, but it’s not like we’re facing shortages tomorrow,” CEO Koji Sato told reporters at the Japan Mobility Show in Tokyo on Wednesday, according to Reuters.
Microsoft‘s Azure, one of the world’s biggest cloud service providers, is suffering outages, triggering widespread internet disruptions across major companies.
According to Downdetector, problems began around 11:30am ET, with reports surging from users who could not access cloud-connected services, websites or apps.
The outage appears to be affecting dozens of platforms that rely on these cloud networks, including Microsoft 365, Xbox, Outlook, Starbucks, Costco and Kroger.
Even popular developer and data tools like Blackbaud and Minecraft are showing connectivity issues.
Downdetector has received nearly 20,000 issue reports from Azure users in the US.
The Microsoft outage comes just days after Amazon Web Services disrupted ‘half the internet.’
The incidents have raised concerns about how much of the global online infrastructure depends on these two companies, which host everything from retail and entertainment platforms to business operations and cloud storage.
Frustrated users have flooded social media to vent, with one post on X reading: ‘First AWS, now Azure goes down. I love it when big companies own half the internet!!!’
In the late 1970s, after ‘global cooling’ armageddon science fell out of fashion, a well-oiled machine comprised of billionaire-funded NGOs, the MSM, Hollywood, woke Wall Street, and a robust fact-checking / censorship cartel – started pushing a cult narrative about the planet’s imminent demisein a hellish inferno of global warming. They’ve blamed everything from cow farts and Taylor Swift’s private jet to two-stroke chainsaws, petrol-powered cars, and whatever else these climate Marxists wanted banned – and forced people into authoritarian bullshit like ‘electric stoves only’ and ’15 minute cities’ and ‘eat the bugs,’ etc.
Now, as data centers are coincidentally projected to need record amounts of electricity, Bill Gates has changed his mind about all of that.
And of course the climate cult was one giant grift – or as one former DOGE worker put it, “a heist on the U.S. Treasury” carried out through propaganda that allowed ‘virtuous’ climate bills to be passed easily.
To see this machine in action, look no further than the number of news articles which warned of a “climate crisis” going back 10 years:
And yet, despite decades of gospel over melting ice caps and doom, Gates simply shreds it and decides it’s ackshually not such a big deal.
To wit, his new forecast is that climate change “won’t lead to humanity’s demise.”
And now, Trump is gloating!
“I (WE!) just won the War on the Climate Change Hoax. Bill Gates has finally admitted that he was completely WRONG on the issue. It took courage to do so, and for that we are all grateful. MAGA!!!” Trump wrote on Truth Social.
Weird that Gates didn’t come to this conclusion before Big Tech needed tons of energy, fast, which means fossil fuels.
It’s important to understand that there is a war being waged on the minds of the American people. The last five years of fake climate doom headlines were merely a move to enrich Democrat allies, such as climate NGOs, with taxpayer funds.
Keep in mind, anyone who questioned the climate change narrative was silenced. Very authoritarian by Democrats and their billionaire ‘Kings’ …
Beijing has agreed to ease rare earth export controls in exchange for lowered tariffs and restrictions from Washington
China has agreed to suspend its latest rare earth export controls in exchange for reciprocal US cuts on tariffs and restrictions, the Chinese Commerce Ministry said in a statement published on its website on Thursday. Beijing’s earlier limits on the critical materials remain in place.
The agreement followed a face-to-face meeting between Chinese President Xi Jinping and his US counterpart Donald Trump in South Korea, as well as economic and trade delegation talks in Kuala Lumpur.
“China will suspend the implementation of relevant export control measures announced on October 9 for one year, and will study and refine specific plans,” the ministry’s statement reads.
Beijing’s restrictions on rare earth mineral exports with dual military use were seen as a response to Washington’s curbs on advanced semiconductors and chipmaking equipment introduced beginning in late 2022, culminating in the Dutch government’s seizure of Chinese owned chipmaker NeXperia in September under US pressure.
China dominates in extraction and processing of rare earth minerals, which are critical for most modern technology from cellphones to missiles.
Under the deal, Washington has agreed to suspend its recent rule expanding export restrictions to any business at least 50% owned by any entity on its “entity list,” the Chinese ministry said.
The US will also suspend its investigation measures targeting Beijing’s maritime, logistics, and shipbuilding industries, and lower fentanyl-related and reciprocal tariffs.
Beijing will adjust its retaliatory measures in response, the statement added.
Trump praised a “great meeting” with Xi, and said that China had agreed to resume purchases of US soybeans and other agricultural products paused during the countries’ recent trade stand-off.
The key to having Big Tech billionaires controlling the public to roll out their agendas of trying to take over the financial system with digital currencies and making everyone comply with their digital surveillance tools so that they can know everything you do and force you to comply to their demands to keep participating in society, is for the public to volunteer to let them make you their slaves.
That’s it. That is all they need, and we saw them do it during COVID with COVID-19 injections, where a majority of the world’s population complied, voluntarily, to take an experimental injection out of fear of a fake virus and pandemic.
Some did refuse to comply, and lost their jobs. But they were by far the minority. Many of those who did comply died or were permanently disabled.
Has the world learned its lesson from the COVID Scam-demic?
Let’s hope so, because the next step is giving everyone a digital ID and requiring them to use that ID along with biometrics like a face scan, eye scan, or palm scan, in order to participate in society and have access to their bank accounts.
[…]
One of the places that has announced a new national Digital ID is the UK, and Brits are generally not very accommodating about this, as you can see in this recent interview with Keir Starmer, who makes it clear that it is still “voluntary,” but that the easier route is to comply.
It will always be like that. They will use fear and convenience to try to get people to accept Digital IDs. We must be willing to give some things up that make our life easier, if we want to protect our privacy and stop Big Tech from making us their slaves.
Opposition is also growing here in the U.S. against Digital IDs.
Here is a recent clip from The Jimmy Dore show who interviews Twila Brase, president of the Citizens’ Council for Health Freedom, and a new bill introduced in the Senate by Rand Paul to stop Real IDs.
[…]
Google begins rolling out age verification [ie digital ID] in app store in response to U.S. laws
Age verification has hit Google’s Play store. Having implemented its age inference system on YouTube, the tech giant has apparently answered calls for age assurance at the app store level.
According to a report from Android Authority, user Artem Russakovskii shared screenshots of the verification prompt in a post on X. The shots in question show a screen that offers users several options for age verification. These include taking a photo of a government ID, facial age estimation through a selfie, credit card verification or email-based age inference, the latter of which is provided by the UK’s Verifymy (and which the author commends as the “quickest, easiest, and most privacy-preserving way to verify your age online”).
The facial age estimation (FAE) option says Google “partners with a company that specializes in estimating age,” but does not include the name of the company. Verifymy does provide biometric facial age estimation, but Google has also developed its own FAE technology, which appears on the Age Check Certification Scheme (ACCS)’s registry of approved providers.
Regardless, Google appears to be anticipating the continued spread of age assurance laws across the U.S. A post from the company points to legislation in Texas, Louisiana and Utah as a catalyst for the app store age check rollout.
The Most Revolutionary Act 